The 10× case
Maria's group starts collecting natural-history data for GM2 activator deficiency
GM2 activator deficiency is ultra-rare: fewer than 30 patients have ever been reported worldwide (NTSAD). By our estimate below (mostly labelled assumptions), a group that starts its own registry waits about 12–28 months before the first family is enrolled. Asclepius found an existing registry that already names the disease.
Estimated speed-up to the milestone
3.3× to 30×
About 9.0× at the middle of both ranges. Calculated from the weeks below, not chosen.
The 10× target falls inside this range.
Usual route: build a new registry
50–121 wk in total
- 1.4–12 wk
Search by hand for anything reusable
AssumptionTrial registries, papers and group websites searched one by one. Confirm by asking patient-group leaders how long their search took.
- 2.12–26 wk
Write a protocol and secure funding
AssumptionA small group drafting its own registry protocol and grant. Confirm with groups that have built a registry, such as those listed in the NCATS Toolkit.
Background - 3.22–31 wk
Ethics approval and site start-up
Published figureAfter funding, the median time to activate a study was 157 days at a single site and 214 days across several sites (Cernik et al. 2021).
Source - 4.12–52 wk
Find and enrol the first families
AssumptionWith fewer than 30 known patients worldwide, a new registry starts with no participants. Confirm against enrolment logs of other ultra-rare registries.
Asclepius route: join the registry that exists
4–15 wk in total
- 1.0–1 wk
Find the registry that already names her disease
From the atlasRegistry Gangliosidoses (NCT04624789) lists Tay-Sachs disease AB variant, the ontology name for GM2 activator deficiency. Found in one search; up to a week to review it with an expert. The week to review it is our assumption.
See the evidence - 2.2–6 wk
Confirm with the sponsor that it is active and eligible
AssumptionIts registered status is UNKNOWN, so the first email asks whether it still enrols. Confirm by recording how long the sponsor takes to reply.
- 3.2–8 wk
Enrol families at a site that is already running
AssumptionNo new protocol or ethics approval for the group itself: families consent into an existing study. Confirm with the registry's enrolment process.
What to validate next
- Registry Gangliosidoses still enrols: its status on ClinicalTrials.gov is UNKNOWN.
- It accepts GM2 activator deficiency genotypes and our families' age range.
- Its consent terms let the group see and reuse the data it contributes.
- Each assumption above, by recording the real number of weeks with the first family.
This is an estimate for one milestone, not a promise of a treatment. Published figures come from studies at other centres; assumptions are ours and are labelled so you can check them.
Asclepius